AU2003233285A1 - Use of peroxovanadium compounds as tumour cell growth suppressor - Google Patents

Use of peroxovanadium compounds as tumour cell growth suppressor Download PDF

Info

Publication number
AU2003233285A1
AU2003233285A1 AU2003233285A AU2003233285A AU2003233285A1 AU 2003233285 A1 AU2003233285 A1 AU 2003233285A1 AU 2003233285 A AU2003233285 A AU 2003233285A AU 2003233285 A AU2003233285 A AU 2003233285A AU 2003233285 A1 AU2003233285 A1 AU 2003233285A1
Authority
AU
Australia
Prior art keywords
bpv
peroxide
cells
tumour
oxygen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003233285A
Other languages
English (en)
Inventor
Charles Doillon
Robert Faure
Pierre Savard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite Laval
Original Assignee
Universite Laval
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite Laval filed Critical Universite Laval
Publication of AU2003233285A1 publication Critical patent/AU2003233285A1/en
Assigned to UNIVERSITE LAVAL reassignment UNIVERSITE LAVAL Amend patent request/document other than specification (104) Assignors: Universite Laval and McGill University
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2003233285A 2002-05-17 2003-05-15 Use of peroxovanadium compounds as tumour cell growth suppressor Abandoned AU2003233285A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CA002386759A CA2386759A1 (fr) 2002-05-17 2002-05-17 Usages therapeutiques des composes peroxometalliques
CA2,386,759 2002-05-17
PCT/CA2003/000738 WO2003097068A1 (fr) 2002-05-17 2003-05-15 Utilisation de composes de peroxovanadium en tant que suppresseurs de croissance de cellules tumorales

Publications (1)

Publication Number Publication Date
AU2003233285A1 true AU2003233285A1 (en) 2003-12-02

Family

ID=29425956

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003233285A Abandoned AU2003233285A1 (en) 2002-05-17 2003-05-15 Use of peroxovanadium compounds as tumour cell growth suppressor

Country Status (4)

Country Link
EP (1) EP1511493A1 (fr)
AU (1) AU2003233285A1 (fr)
CA (2) CA2386759A1 (fr)
WO (1) WO2003097068A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003031930A2 (fr) * 2001-10-09 2003-04-17 The Johns Hopkins University Phosphatase associee a une metastase

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000057860A2 (fr) * 1999-03-26 2000-10-05 Centre For Translational Research In Cancer Composes de peroxovanadium utilises comme agents antineoplasiques dans le traitement du cancer
CA2280249A1 (fr) * 1999-08-12 2001-02-12 Universite Laval Composes de vanadium utilises comme facteurs anti-angiogeniques et comme inhibiteurs de production d'endotheline

Also Published As

Publication number Publication date
CA2525672A1 (fr) 2003-11-27
WO2003097068A1 (fr) 2003-11-27
CA2386759A1 (fr) 2003-11-17
EP1511493A1 (fr) 2005-03-09

Similar Documents

Publication Publication Date Title
US6284786B1 (en) Treatment of cancer using lipoic acid in combination with ascorbic acid
AU2005316295B2 (en) Method for extending lifespan and delaying the onset of age-related disease
KR101413731B1 (ko) 비뇨 생식기암 및 이의 전이 치료용 비소산, 이것의나트륨염 및 이것의 유도체를 함유하는 약학 조성물
JP5727000B2 (ja) 腫瘍の処置のためのエポトシドのアナログ
CN104220057A (zh) 药物组合物和方法
KR100861428B1 (ko) 암 치료용 지방산 유사체
Martoni et al. Capecitabine plus oxaliplatin (xelox) versus protracted 5-fluorouracil venous infusion plus oxaliplatin (pvifox) as first-line treatment in advanced colorectal cancer: a GOAM phase II randomised study (FOCA trial)
Stratford et al. Induction of tumour hypoxia post-irradiation: a method for increasing the sensitizing efficiency of misonidazole and RSU 1069 in vivo
Lv et al. Styrene-maleic acid copolymer-encapsulated carbon monoxide releasing molecule-2 (SMA/CORM-2) suppresses proliferation, migration and invasion of colorectal cancer cells in vitro and in vivo
Huang et al. Bortezomib prodrug catalytic nanoreactor for chemo/chemodynamic therapy and macrophage re-education
CN101917993B (zh) 用于治疗癌症的化合物
Hang et al. Mesoporous nanodrug delivery system: a powerful tool for a new paradigm of remodeling of the tumor microenvironment
JP6194322B2 (ja) 乳酸脱水素酵素阻害剤およびそれを含有する医薬品
WO2018203127A1 (fr) Compositions pour le traitement de tumeurs malignes et d'états précancéreux, procédés d'utilisation de celles-ci et procédés de fabrication de médicaments
NZ278028A (en) Medicaments comprising vanadate compounds
CN106974908A (zh) 含有hdac抑制剂和ire1抑制剂的药物组合物及用途
EP0794786B1 (fr) Utilisation d'inositoltriphosphate pour la preparation de medicaments
AU2003233285A1 (en) Use of peroxovanadium compounds as tumour cell growth suppressor
KR20180006747A (ko) 암에 대한 방사선 치료 증진용 약학적 조성물
CN115068615B (zh) 一种“开源节流”型逆转乏氧抗肿瘤药物组合物及其应用
CN115612902B (zh) 一种协同tace抗肝癌作用的镁基合金微米粒子及制备方法
CA2396704A1 (fr) Dianthraquinones polycycliques utilisees comme agents anticancereux et anti-angiogeniques
Horsman et al. The ability of nicotinamide to inhibit the growth of a C3H mouse mammary carcinoma
Gargano et al. Epirubicin, cisplatin and continuous-infusion 5-fluorouracil (ECF regimen) in the treatment of advanced colorectal cancer
CN115429882A (zh) 伤害性感觉神经细胞调控药物的用途

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE APPLICANT FROM UNIVERSITE LAVAL AND MCGILL UNIVERSITY TO UNIVERSITE LAVAL.

MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period